Comerica Bank Sells 1,364 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Comerica Bank lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,187 shares of the biopharmaceutical company's stock after selling 1,364 shares during the quarter. Comerica Bank's holdings in Regeneron Pharmaceuticals were worth $10,106,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Voleon Capital Management LP acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth about $478,000. PDT Partners LLC boosted its stake in Regeneron Pharmaceuticals by 101.9% during the 4th quarter. PDT Partners LLC now owns 6,058 shares of the biopharmaceutical company's stock valued at $4,315,000 after purchasing an additional 3,057 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its position in Regeneron Pharmaceuticals by 475.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 22,388 shares of the biopharmaceutical company's stock valued at $15,948,000 after buying an additional 18,496 shares during the last quarter. Lido Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 9.5% in the 4th quarter. Lido Advisors LLC now owns 2,314 shares of the biopharmaceutical company's stock worth $1,649,000 after buying an additional 201 shares during the last quarter. Finally, Northern Trust Corp grew its stake in Regeneron Pharmaceuticals by 14.8% in the 4th quarter. Northern Trust Corp now owns 1,054,829 shares of the biopharmaceutical company's stock valued at $751,386,000 after purchasing an additional 136,184 shares during the period. Institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Bernstein Bank lowered their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. TD Cowen decreased their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a report on Tuesday, February 4th. Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research report on Monday, January 27th. BMO Capital Markets dropped their target price on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Finally, Sanford C. Bernstein dropped their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $892.60.

Regeneron Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ:REGN traded down $2.03 on Monday, hitting $603.58. 1,124,250 shares of the company traded hands, compared to its average volume of 746,539. The company has a market cap of $65.99 billion, a PE ratio of 15.77, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a 52 week low of $525.99 and a 52 week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $624.42 and a 200-day simple moving average of $704.67.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the company earned $9.55 EPS. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.58%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.